Impact Factor 4.019
2017 JCR, Clarivate Analytics 2018

The world's most-cited Microbiology journal

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Microbiol. | doi: 10.3389/fmicb.2019.01173

Curdlan limits Mycobacterium tuberculosis survival through STAT-1 regulated Nitric oxide production

 Shikha Negi1,  Susanta Pahari1, Deepjyoti k. Das1, Nargis Khan1 and  Javed N. Agrewala1*
  • 1Institute of Microbial Technology (CSIR), India

Host-directed therapies have emerged as an innovative and promising approach in tuberculosis (TB) treatment due to the observed limitations of current TB regimen such as lengthy duration and emergence of drug resistance. Thus, we explored the role of curdlan as a novel strategy to activate macrophages by boosting their innate immune response against Mycobacterium tuberculosis (Mtb). The aim of the study was to investigate the role of curdlan in restricting the Mtb growth both in vitro and in vivo. Further, the immunomodulatory potential of curdlan (beta glucan polysaccharide) against Mtb and the underlying mechanism is largely unknown. We found that curdlan treatment enhanced the antigen presentation, pro-inflammatory cytokines, Mtb uptake and killing activity of macrophages. In vivo studies showed that curdlan therapy significantly reduced the Mtb burden in lung and spleen of mice. Administration of curdlan triggered the protective Th1 and Th17 immunity while boosting the central and effector memory response in Mtb infected mice. Curdlan mediated anti-Mtb activity is through signal transducer and activator of transcription-1 (STAT-1), which regulates nitric oxide (NO) production through inducible NO synthase (iNOS) induction; along with this activation of nuclear factor kappa B (NF-ĸB) was also evident in Mtb infected macrophages upon curdlan stimulation. Thus, we demonstrate that curdlan exerts effective anti-tuberculous activity to be used as a potential host-directed therapy against Mtb.

Keywords: Macrophages, Curdlan, iNOS, T cells, Host-directed therapy, Tuberculosis

Received: 19 Dec 2018; Accepted: 08 May 2019.

Edited by:

Lia Danelishvili, Oregon State University, United States

Reviewed by:

Roland Lang, University Hospital Erlangen, Germany
Yusuf Akhter, Babasaheb Bhimrao Ambedkar University, India
Shashank Gupta, Brown University, United States  

Copyright: © 2019 Negi, Pahari, Das, Khan and Agrewala. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Javed N. Agrewala, Institute of Microbial Technology (CSIR), Chandigarh, 160036, Punjab, India,